FAP-targeted PET/NIR in Lung Malignant Tumors

01 Apr 20264 min read0 viewsOBSERVATIONAL Trial

GIST

RECRUITING · OBSERVATIONAL · Non-Small Cell Lung Cancer · Enrollment 200 · Sponsor: Peking University People's Hospital

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 01 Apr 2026. The item focuses on FAP-targeted PET/NIR in Lung Malignant Tumors. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT07498933

Open Original Source More Feed Items

Related by Condition/Drug

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

JAMA OncRelated by Conditionlung cancer

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Oncology • 14 May 2026

NatureRelated by Conditionlung cancer

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

ClinicalTrialsRelated by Conditionlung cancer

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Oncology • 14 Apr 2026

ClinicalTrialsRelated by Conditionlung cancer

Pilot Study of Spatially Fractionated Radiation Therapy in Extra-Cranial Soft Tissue Metastases

Oncology • 30 Mar 2026

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial

Oncology • 23 Apr 2026

Feed Metadata

Source

ClinicalTrials.gov